NMPA Clears Kelun-Harbour Asthma Bispecific IND
Kelun Harbour SKB575 HBM7575 NMPA asthma IND clearance expands the partners' long-acting TSLP bispecific into a second major indication. The companies said on July 15, 2026 that China regulators approved clinical development in asthma after atopic dermatitis dosing had already begun.
Contents9 sections
Key Takeaways
- NMPA approved an IND for SKB575/HBM7575 in asthma.
- Asset is a long-acting bispecific against TSLP plus an undisclosed second target.
- Phase 1 atopic dermatitis dosing is already underway.
- Preclinical half-life data suggest potential for >3-month dosing intervals — still unproven in humans.
SKB575/HBM7575 asthma IND at a glance
| Field | Detail |
|---|---|
| Candidate | SKB575 / HBM7575 |
| Sponsors | Kelun-Biotech (lead); Harbour BioMed (co-developer) |
| Mechanism | Long-acting bispecific: TSLP + undisclosed antigen |
| Regulator action | China NMPA asthma IND approval (July 15, 2026) |
| Other IND | Atopic dermatitis — Phase 1 dosing started |
| Route / interval goal | Subcutaneous; potential >3-month interval (preclinical) |
What did the partners announce?
Kelun-Biotech and Harbour BioMed said NMPA cleared SKB575/HBM7575 for asthma trials, positioning the molecule against upstream type-2 inflammation drivers. Kelun leads design, global development, and commercialization under the collaboration, with Harbour sharing economics as agreed.
Source: Kelun-Biotech and Harbour BioMed's July 15 PR Newswire IND release.
Why target TSLP in asthma?
TSLP sits upstream of Th2 pathways that drive eosinophilic and allergic airway disease. An approved anti-TSLP monoclonal antibody already validates the target class in severe asthma; a bispecific that adds a second inflammatory node could broaden control if clinical data support synergy without excess immunosuppression.
Background on TSLP-pathway medicines and FDA labeling for the class is available via FDA's drugs information hub. Emerging asthma studies can be tracked on ClinicalTrials.gov.
What should developers watch?
- First-in-human PK confirming multi-month half-life claims
- Safety versus infection risk when dual pathways are blocked
- Asthma exacerbation and lung-function endpoints once efficacy cohorts open
- How atopic dermatitis learnings transfer to airway dosing
An IND is permission to study, not evidence of efficacy. Competitive TSLP and IL-4/13/5 biologics already set a high bar for convenience and exacerbation reduction in China and globally. For APAC pipeline desks, the dual-indication start (atopic dermatitis plus asthma) is the near-term signal: it shows Kelun and Harbour are willing to run parallel type-2 programs rather than sequencing one indication to completion first.
Investigators will still need China-appropriate inclusion criteria for eosinophilic versus mixed asthma phenotypes, steroid-sparing endpoints, and clear stopping rules if dual blockade raises infection or hypereosinophilia concerns. Until those protocols and early PK/PD readouts appear, the asset should be tracked as a clinical-entry milestone, not as a late-stage competitor to marketed biologics.
What remains uncertain?
The second antigen remains undisclosed, limiting independent mechanism assessment. No asthma efficacy data were released with the IND notice. Global development timelines outside China were not detailed beyond Kelun's lead role.
Related NovaPharma coverage
- Orzeyful: NMPA Clears First OX2R Agonist for NT1
- NMPA Approves Ciprocopan for PNH in China
- China trial speed draws oncology go-East plans
Frequently Asked Questions
What IND did NMPA approve for SKB575/HBM7575?
On July 15, 2026, Kelun-Biotech and Harbour BioMed said China's National Medical Products Administration approved an Investigational New Drug application for SKB575/HBM7575, a long-acting bispecific antibody targeting TSLP and an undisclosed second antigen, for the treatment of asthma.
What other indication is already in the clinic?
The partners said the first participant has already been dosed in a Phase 1 study of SKB575/HBM7575 for atopic dermatitis, giving the bispecific two major type-2 inflammatory indications cleared for clinical development in China.
What dosing profile are the companies targeting?
Based on preclinical half-life data, the companies said the anticipated human half-life could support dosing intervals of more than three months with subcutaneous administration. That claim is preclinical and must be confirmed in clinical pharmacology studies.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for SKB575.
Unlock full calendar →Kelun-Biotech pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
